Etsuko Miyagi1, Yasuyo Maruyama2, Tae Mogami2, Reiko Numazaki2, Atsuko Ikeda3, Hiroshi Yamamoto3, Fumiki Hirahara2. 1. Department of Obstetrics and Gynecology, Yokohama City University Hospital, 3-9 Fukuura, Kanazawa-ku, Yokohama City, Kanagawa, 236-0004, Japan. emiyagi@med.yokohama-cu.ac.jp. 2. Department of Obstetrics and Gynecology, Yokohama City University Hospital, 3-9 Fukuura, Kanazawa-ku, Yokohama City, Kanagawa, 236-0004, Japan. 3. Institute for Innovation, Ajinomoto Co. Inc., Suzuki 1-1, Kawasaki City, Kanagawa, 210-8681, Japan.
Abstract
BACKGROUND: We previously developed a new plasma amino acid profile-based index (API) to detect ovarian, cervical, and endometrial cancers. Here, we compared API to serum cancer antigen 125 (CA125) for distinguishing epithelial ovarian malignant tumors from benign growths. METHODS: API and CA125 were measured preoperatively in patients with ovarian tumors, which were later classified into 59 epithelial ovarian cancers, 21 epithelial borderline malignant tumors, and 97 benign tumors including 40 endometriotic cysts. The diagnostic accuracy and cutoff points of API were evaluated using receiver operating characteristic (ROC) curves. RESULTS: The area under the ROC curves showed the equivalent performance of API and CA125 to discriminate between malignant/borderline malignant and benign tumors (both 0.77), and API was superior to CA125 for discrimination between malignant/borderline malignant lesions and endometriotic cysts (API, 0.75 vs. CA125, 0.59; p < 0.05). At the API cutoff level of 6.0, API and CA125 had equal positive rates of detecting cancers and borderline malignancies (API, 0.71 vs. CA125, 0.74; p = 0.84) or cancers alone (API, 0.73 vs. CA125, 0.85; p = 0.12). However, API had a significantly lower detection rate of benign endometriotic cysts (0.35; 95 % CI, 0.21-0.52) compared with that of CA125 (0.65; 95 % CI, 0.48-0.79) (p < 0.05). CONCLUSIONS: API is an effective new tumor marker to detect ovarian cancers and borderline malignancies with a low false-positive rate for endometriosis. A large-scale prospective clinical study using the cutoff value of API determined in this study is warranted to validate API for practical clinical use.
BACKGROUND: We previously developed a new plasma amino acid profile-based index (API) to detect ovarian, cervical, and endometrial cancers. Here, we compared API to serum cancer antigen 125 (CA125) for distinguishing epithelial ovarian malignant tumors from benign growths. METHODS:API and CA125 were measured preoperatively in patients with ovarian tumors, which were later classified into 59 epithelial ovarian cancers, 21 epithelial borderline malignant tumors, and 97 benign tumors including 40 endometriotic cysts. The diagnostic accuracy and cutoff points of API were evaluated using receiver operating characteristic (ROC) curves. RESULTS: The area under the ROC curves showed the equivalent performance of API and CA125 to discriminate between malignant/borderline malignant and benign tumors (both 0.77), and API was superior to CA125 for discrimination between malignant/borderline malignant lesions and endometriotic cysts (API, 0.75 vs. CA125, 0.59; p < 0.05). At the API cutoff level of 6.0, API and CA125 had equal positive rates of detecting cancers and borderline malignancies (API, 0.71 vs. CA125, 0.74; p = 0.84) or cancers alone (API, 0.73 vs. CA125, 0.85; p = 0.12). However, API had a significantly lower detection rate of benign endometriotic cysts (0.35; 95 % CI, 0.21-0.52) compared with that of CA125 (0.65; 95 % CI, 0.48-0.79) (p < 0.05). CONCLUSIONS:API is an effective new tumor marker to detect ovarian cancers and borderline malignancies with a low false-positive rate for endometriosis. A large-scale prospective clinical study using the cutoff value of API determined in this study is warranted to validate API for practical clinical use.
Authors: Rodney P Rocconi; Kellie S Matthews; Meredith K Kemper; Kelly E Hoskins; Warner K Huh; J Michael Straughn Journal: Gynecol Oncol Date: 2009-05-17 Impact factor: 5.482
Authors: A Cascino; M Muscaritoli; C Cangiano; L Conversano; A Laviano; S Ariemma; M M Meguid; F Rossi Fanelli Journal: Anticancer Res Date: 1995 Mar-Apr Impact factor: 2.480
Authors: Karen H Lu; Steven Skates; Mary A Hernandez; Deepak Bedi; Therese Bevers; Leroy Leeds; Richard Moore; Cornelius Granai; Steven Harris; William Newland; Olasunkanmi Adeyinka; Jeremy Geffen; Michael T Deavers; Charlotte C Sun; Nora Horick; Herbert Fritsche; Robert C Bast Journal: Cancer Date: 2013-08-26 Impact factor: 6.860
Authors: Agnieszka Horala; Szymon Plewa; Pawel Derezinski; Agnieszka Klupczynska; Jan Matysiak; Ewa Nowak-Markwitz; Zenon J Kokot Journal: Int J Environ Res Public Health Date: 2021-02-23 Impact factor: 3.390